541 related articles for article (PubMed ID: 32933141)
1. Predicting Nonalcoholic Fatty Liver Disease through a Panel of Plasma Biomarkers and MicroRNAs in Female West Virginia Population.
Pillai SS; Lakhani HV; Zehra M; Wang J; Dilip A; Puri N; O'Hanlon K; Sodhi K
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32933141
[TBL] [Abstract][Full Text] [Related]
2. Irisin in patients with nonalcoholic fatty liver disease.
Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
[TBL] [Abstract][Full Text] [Related]
3. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
4. miRNA-103: molecular link between insulin resistance and nonalcoholic fatty liver disease.
Xu Q; Li Y; Shang YF; Wang HL; Yao MX
World J Gastroenterol; 2015 Jan; 21(2):511-6. PubMed ID: 25593466
[TBL] [Abstract][Full Text] [Related]
5. A micro-RNA expression signature for human NAFLD progression.
Guo Y; Xiong Y; Sheng Q; Zhao S; Wattacheril J; Flynn CR
J Gastroenterol; 2016 Oct; 51(10):1022-30. PubMed ID: 26874844
[TBL] [Abstract][Full Text] [Related]
6. miR33a/miR33b* and miR122 as Possible Contributors to Hepatic Lipid Metabolism in Obese Women with Nonalcoholic Fatty Liver Disease.
Auguet T; Aragonès G; Berlanga A; Guiu-Jurado E; Martí A; Martínez S; Sabench F; Hernández M; Aguilar C; Sirvent JJ; Del Castillo D; Richart C
Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669236
[TBL] [Abstract][Full Text] [Related]
7. Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes.
Bayliss J; Ooi GJ; De Nardo W; Shah YJH; Montgomery MK; McLean C; Kemp W; Roberts SK; Brown WA; Burton PR; Watt MJ
Front Endocrinol (Lausanne); 2021; 12():642432. PubMed ID: 33746906
[TBL] [Abstract][Full Text] [Related]
8. Circulating microRNA expression and nonalcoholic fatty liver disease in adolescents with severe obesity.
Li YJ; Baumert BO; Stratakis N; Goodrich JA; Wu HT; He JX; Zhao YQ; Aung MT; Wang HX; Eckel SP; Walker DI; Valvi D; La Merrill MA; Ryder JR; Inge TH; Jenkins T; Sisley S; Kohli R; Xanthakos SA; Baccarelli AA; McConnell R; Conti DV; Chatzi L
World J Gastroenterol; 2024 Jan; 30(4):332-345. PubMed ID: 38313232
[TBL] [Abstract][Full Text] [Related]
9. Investigating Molecular Connections of Non-alcoholic Fatty Liver Disease with Associated Pathological Conditions in West Virginia for Biomarker Analysis.
Sharma DL; Lakhani HV; Klug RL; Snoad B; El-Hamdani R; Shapiro JI; Sodhi K
J Clin Cell Immunol; 2017 Oct; 8(5):. PubMed ID: 29177105
[TBL] [Abstract][Full Text] [Related]
10. Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease.
Kim TH; Lee Y; Lee YS; Gim JA; Ko E; Yim SY; Jung YK; Kang S; Kim MY; Kim H; Kim BH; Kim JH; Seo YS; Yim HJ; Yeon JE; Um SH; Byun KS
Sci Rep; 2021 Jul; 11(1):14639. PubMed ID: 34282172
[TBL] [Abstract][Full Text] [Related]
11. Osteocalcin and osteoprotegerin levels and their relationship with adipokines and proinflammatory cytokines in children with nonalcoholic fatty liver disease.
El Amrousy D; El-Afify D
Cytokine; 2020 Nov; 135():155215. PubMed ID: 32731119
[TBL] [Abstract][Full Text] [Related]
12. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives.
Hochreuter MY; Dall M; Treebak JT; Barrès R
Mol Metab; 2022 Nov; 65():101581. PubMed ID: 36028120
[TBL] [Abstract][Full Text] [Related]
13. Decreased lipid metabolism but increased FA biosynthesis are coupled with changes in liver microRNAs in obese subjects with NAFLD.
Latorre J; Moreno-Navarrete JM; Mercader JM; Sabater M; Rovira Ò; Gironès J; Ricart W; Fernández-Real JM; Ortega FJ
Int J Obes (Lond); 2017 Apr; 41(4):620-630. PubMed ID: 28119530
[TBL] [Abstract][Full Text] [Related]
14. Existence of a Strong Correlation of Biomarkers and miRNA in Females with Metabolic Syndrome and Obesity in a Population of West Virginia.
Goguet-Rubio P; Klug RL; Sharma DL; Srikanthan K; Puri N; Lakhani VH; Nichols A; O'Hanlon KM; Abraham NG; Shapiro JI; Sodhi K
Int J Med Sci; 2017; 14(6):543-553. PubMed ID: 28638270
[No Abstract] [Full Text] [Related]
15. Biomarkers in nonalcoholic fatty liver disease.
Neuman MG; Cohen LB; Nanau RM
Can J Gastroenterol Hepatol; 2014 Dec; 28(11):607-18. PubMed ID: 25575111
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of aerobic plus resistance training on the adipokines and neuropeptides in nonalcoholic fatty liver disease obese adolescents.
de Piano A; de Mello MT; Sanches Pde L; da Silva PL; Campos RM; Carnier J; Corgosinho F; Foschini D; Masquio DL; Tock L; Oyama LM; do Nascimento CM; Tufik S; Dâmaso AR
Eur J Gastroenterol Hepatol; 2012 Nov; 24(11):1313-24. PubMed ID: 22932160
[TBL] [Abstract][Full Text] [Related]
17. Adipokines and C-reactive protein in relation to bone mineralization in pediatric nonalcoholic fatty liver disease.
Pacifico L; Bezzi M; Lombardo CV; Romaggioli S; Ferraro F; Bascetta S; Chiesa C
World J Gastroenterol; 2013 Jul; 19(25):4007-14. PubMed ID: 23840146
[TBL] [Abstract][Full Text] [Related]
18. Exosomal miR-122, miR-128, miR-200, miR-298, and miR-342 as novel diagnostic biomarkers in NAFL/NASH: Impact of LPS/TLR-4/FoxO3 pathway.
Samy AM; Kandeil MA; Sabry D; Abdel-Ghany AA; Mahmoud MO
Arch Pharm (Weinheim); 2024 Apr; 357(4):e2300631. PubMed ID: 38574101
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease.
Tan Y; Ge G; Pan T; Wen D; Gan J
PLoS One; 2014; 9(8):e105192. PubMed ID: 25141008
[TBL] [Abstract][Full Text] [Related]
20. Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease.
Okamoto K; Koda M; Okamoto T; Onoyama T; Miyoshi K; Kishina M; Matono T; Kato J; Tokunaga S; Sugihara T; Hiramatsu A; Hyogo H; Tobita H; Sato S; Kawanaka M; Hara Y; Hino K; Chayama K; Murawaki Y; Isomoto H
PLoS One; 2020; 15(2):e0219412. PubMed ID: 32106257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
